Trial Profile
Multicentre, randomised, open label, non-inferiority active-controlled trial to evaluate the efficacy and safety of deferiprone compared to deferasirox in paediatric patients aged from 1 month to less than 18 years of age affected by transfusion-dependent haemoglobinopathies
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Deferiprone (Primary) ; Deferasirox
- Indications Haemosiderosis
- Focus Therapeutic Use
- Acronyms DEEP-2
- 06 Nov 2019 Results asessing neutropenia in children treated with Deferiprone or Deferasirox released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 19 Oct 2017 Status changed from active, no longer recruiting to completed.
- 21 Mar 2017 Planned End Date changed from 1 Apr 2017 to 1 Aug 2017.